Partners for Life

Delivering recombinant proteins, viral vaccines and gene therapies to patients requires commitment and partnership. As a CDMO our focus is to combine technical leadership in cell culture, microbial fermentation and viral vectors with world class GMP manufacturing facilities to advance tomorrow’s medicines.

25+ Years of Experience

What We Do

Formulation Development

Balancing the need for speed with robust science with comprehensive and modern analytical and formulation capabilities and technical expertise
Learn More

Saturn

A Monoclonal Antibody Platform for reliable delivery of mAb based therapeutics
Learn More

Apollo Mammalian Expression

A Mammalian Expression Platform developed for robust, high levels of monoclonal antibody expression designed with manufacturability for the entire life of your product
Learn More

Paveway Microbial Expression

Incorporating key aspects for the delivery of an E.coli based expression process with industry leading titers and suitable for large-scale manufacture using antibiotic-free fermentation
Learn More

Gene Therapy

Delivering scalable Gene Therapy processes.
Learn More

Thought Leadership

You are about to embark on a clinical journey—be it early, pre-clinical investigation or a later phase of the product lifecycle—it’s good to know Thought Leaders are paving the way.
Learn More
Featured
brochures
publications
case-study
whitepaper
Brochure

pAVEway Advanced Microbial Expression Platform

Learn more about our innovative microbial expression system for large-scale production of antibiotic-free therapeutic proteins.

Learn More
Brochure

Viral Products Brochure

Learn more about our Viral Products Expertise Experience & Capabilities

Learn More
Brochure

Corporate CDMO Booklet

View our interactive booklet to learn how we can become Partners for Life, Advancing tomorrow's medicines.

Learn More
Publications

Designing and Operating Flexible Advanced Therapies Manufacturing

Learn More
Publications

Mass Spectrometric Conjugate Characterization: Process Qualification of Recombinant Protein–Hapten Conjugation

Here we present case studies in development of reliable methods based on mass spectrometry (MS) to characterize a protein–hapten drug substance during late-phase process validation. This protein is modified by succinylation to enable conjugation with an aminated hapten.

Learn More
Publications

Rapid Development of High-Quality, Robust Mammalian Cell Culture Manufacturing Processes

Learn the approach that our scientists uses to accelerate the development process from gene to finish by shortening the timeline, incorporating quality by design (QbD) principles, and designing the process to be as robust as possible.

Learn More
Case Study

Expanding Single-Use Biomanufacturing

There are key considerations to take into account when expanding with single-use biologics manufacturing. These technologies readily enable duplicate capacity.

Learn More
Case Study

Single-Use Biologics Manufacturing for Long Term Needs

CDMOs can ensure to meet demand with single-use biologics manufacturing technologies. We have 5 key considerations for securing your supply chain and future-proofing your organization.

Learn More
Case Study

Assessing Biologics Manufacturing Needs

When determining the right type of biomanufacturing capacity for your biologics manufacturing needs, there are key considerations to take into account.

Learn More
Whitepapers

Three steps to start you on the path to obtaining the ‘best’ recombinant CHO cell line

The keys to developing biomanufacturing processes which are efficient, robust and of high quality start during cell line and process development.

Learn More
Whitepapers

Xtalks from gene to manufacturing

Application of efficient cell line development strategies to deliver reliable, high quality biomanufacturing processes

Learn More
Whitepapers

pAVEwayTM expression system for the efficient expression of therapeutic proteins

The Escherichia coli pAVEwayTM expression system described here has been developed to ensure high product titres and efficient scale up to GMP manufacture, whilst minimizing many common issues seen in other expression systems, such as ‘leaky’ expression (expression of recombinant protein in the absence of inducer).

Learn More